ATRC News and Press, AtriCure Inc. From 11/01/23

AtriCure Inc. (ATRC) is expected to report $-0.3 for Q3 2023

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2023 Healthcare Conference. ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2023 financial results on Wednesday, N...

2023-09-04 12:21:00 ET Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. The investment bank noted that medtech growth slowed slightly in Q2, expanding by only 8.3% co...

2023-08-29 22:32:23 ET Summary AtriCure stock has been heavily sold off following its Q2 numbers, despite strong performance and a revised full-year outlook. The company has seen growth across all segments, with around 20% growth and profits posted at the adj. EBITDA line. Val...

2023-07-25 19:40:03 ET AtriCure, Inc. (ATRC) Q2 2023 Earnings Conference Call July 25, 2023 04:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick - CFO Conference Call Participants ...

2023-07-25 16:13:00 ET AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.11 beats by $0.19 . Revenue of $100.9M (+19.4% Y/Y) beats by $3.41M . For further details see: AtriCure GAAP EPS of -$0.11 beats by $0.19, revenue of $100.9M beats by $3.41M

Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvem...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 2...